| Symbol | ASND |
|---|---|
| Name | ASCENDIS PHARMA A/S |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | TUBORG BOULEVARD 12, HELLERUP, DK-2900, Denmark |
| Telephone | +45 70222244 |
| Fax | — |
| — | |
| Website | https://www.ascendispharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001612042 |
| Description | Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firms product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China. Additional info from NASDAQ: |
Bodenhoff Mads 🟡 adjusted position in 3.0K shares (1 derivative) of Ascendis Pharma A/S (ASND) at $270.19 ($1.5M) Transaction Date: Sep 08, 2026 | Filing ID: 000409
Read moreFirst Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
Read more📋 Bodenhoff Mads (Officer) plans to sell 3K shares of Ascendis Pharma A/S (at $270.19 each, total $811K) Filed: Sep 08, 2026 | ID: 000432
Read moreAscendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Read moreAscendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
Read more📋 HOLTUG LARS (Director) plans to sell 236 shares of Ascendis Pharma A/S (at $264.13 each, total $62K) Filed: Sep 02, 2026 | ID: 000330
Read moreAscendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)
Read moreAscendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
Read moreBIENAIME JEAN JACQUES 🟢 acquired 2.0K shares of Ascendis Pharma A/S (ASND) at $246.91 Transaction Date: Aug 14, 2026 | Filing ID: 000360
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05654701 | Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroid… | — | Hypoparathyroidism | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT07081997 | A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of P… | Phase3 | Hypoparathyroidism | Recruiting | 2026-05-07 | 2028-06-01 | ClinicalTrials.gov |
| NCT07706764 | A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents Wi… | Phase3 | Hypoparathyroidism | Recruiting | 2026-04-22 | 2031-08-01 | ClinicalTrials.gov |
| NCT07264634 | A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating… | — | Hypoparathyroidism | Recruiting | 2026-03-19 | 2027-08-01 | ClinicalTrials.gov |
| NCT07345494 | A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Foll… | — | Hypoparathyroidism | Recruiting | 2026-02-18 | 2036-01-01 | ClinicalTrials.gov |
| NCT07221851 | Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compare… | Phase3 | Turner Syndrome | Recruiting | 2025-12-12 | 2029-03-01 | ClinicalTrials.gov |
| NCT06732895 | A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescent… | Phase2 | Achondroplasia | Recruiting | 2024-12-10 | 2027-09-01 | ClinicalTrials.gov |
| NCT06433557 | A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Nave… | Phase2 | Achondroplasia | Active_Not_Recruiting | 2024-07-26 | 2027-11-01 | ClinicalTrials.gov |
| NCT06079398 | A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With … | Phase2 | Achondroplasia | Recruiting | 2024-01-23 | 2028-12-01 | ClinicalTrials.gov |
| NCT05980598 | TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for A… | Phase2 | Head and Neck Neoplasms | Terminated | 2023-09-29 | 2025-03-28 | ClinicalTrials.gov |
| NCT05929807 | A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of… | Phase2 | Achondroplasia | Enrolling_By_Invitation | 2023-06-21 | 2039-03-01 | ClinicalTrials.gov |
| NCT05820672 | A US Non-interventional, Effectiveness and Safety Study of Patients Treated Wit… | — | Growth Hormone Deficiency | Recruiting | 2023-03-20 | 2033-03-01 | ClinicalTrials.gov |
| NCT05775523 | A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatr… | — | Growth Hormone Deficiency | Recruiting | 2023-03-20 | 2033-03-01 | ClinicalTrials.gov |
| NCT05598320 | A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With … | Phase2 | Achondroplasia | Completed | 2023-03-03 | 2025-08-13 | ClinicalTrials.gov |
| NCT05690386 | A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatro… | Phase2 | Turner Syndrome | Active_Not_Recruiting | 2023-02-15 | 2027-12-01 | ClinicalTrials.gov |
| NCT05081609 | A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in… | Phase1 | Advanced Solid Tumor | Active_Not_Recruiting | 2022-01-11 | 2029-08-01 | ClinicalTrials.gov |
| NCT05171855 | A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Ad… | Phase3 | Adult Growth Hormone Deficiency | Completed | 2021-12-16 | 2024-12-23 | ClinicalTrials.gov |
| NCT04799054 | A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients Wi… | Phase1 | Advanced Solid Tumor | Terminated | 2021-03-18 | 2025-12-02 | ClinicalTrials.gov |
| NCT04701203 | A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Adm… | Phase3 | Hypoparathyroidism | Completed | 2021-02-16 | 2025-01-21 | ClinicalTrials.gov |
| NCT04615273 | A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin Wit… | Phase3 | Growth Hormone Deficiency | Completed | 2020-12-03 | 2023-12-01 | ClinicalTrials.gov |
| NCT04085523 | A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Tr… | Phase2 | Achondroplasia | Completed | 2020-06-24 | 2024-10-01 | ClinicalTrials.gov |
| NCT04326374 | Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Ch… | Phase3 | Growth Hormone Deficiency | Unknown | 2019-12-30 | 2022-04-01 | ClinicalTrials.gov |
| NCT04009291 | A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in … | Phase2 | Hypoparathyroidism | Completed | 2019-08-27 | 2025-04-17 | ClinicalTrials.gov |
| NCT03875534 | A Multi-center, Longitudinal, Observational Study of Children With Achondroplas… | — | Achondroplasia | Completed | 2019-06-19 | 2024-01-12 | ClinicalTrials.gov |
| NCT03344458 | A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children… | Phase3 | Growth Hormone Deficiency, Pediatric | Completed | 2017-12-19 | 2023-02-21 | ClinicalTrials.gov |
| NCT03305016 | A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Grow… | Phase3 | Growth Hormone Deficiency, Pediatric | Completed | 2017-11-13 | 2019-03-19 | ClinicalTrials.gov |
| NCT02781727 | A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly… | Phase3 | Growth Hormone Deficiency, Pediatric | Completed | 2016-12-13 | 2019-01-17 | ClinicalTrials.gov |
| NCT03803163 | A Safety, Tolerability and Pharmacokinetics Study of TransCon Treprostinil in H… | Phase1 | Healthy Volunteers | Terminated | 2015-01-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01947907 | Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekl… | Phase2 | Growth Hormone Deficiency (GHD) | Completed | 2013-07-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01247675 | A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) i… | Phase2 | Adult Growth Hormone Deficiency | Completed | 2010-11-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01010425 | Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH) | Phase1 | Healthy | Completed | 2009-11-01 | 2010-05-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| TransCon CNP | Other | Phase PHASE2 | Achondroplasia | ENROLLING_BY_INVITATION | NCT05929807 |
| TransCon CNP | Other | Phase PHASE2 | Achondroplasia | ENROLLING_BY_INVITATION | NCT05929807 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide | Other | Preclinical | Hypoparathyroidism | RECRUITING | NCT07264634 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Palopegteriparatide | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07706764 |
| Palopegteriparatide | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07706764 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Omnitrope | Other | Phase PHASE2 | Adult Growth Hormone Deficiency | COMPLETED | NCT01247675 |
| ACP-001 (TransCon hGH) | Other | Phase PHASE2 | Adult Growth Hormone Deficiency | COMPLETED | NCT01247675 |
| Human Growth Hormone | Other | Phase PHASE2 | Growth Hormone Deficiency (GHD) | COMPLETED | NCT01947907 |
| ACP-001 | Other | Phase PHASE2 | Growth Hormone Deficiency (GHD) | COMPLETED | NCT01947907 |
| TransCon hGH | Other | Phase PHASE3 | Growth Hormone Deficiency, Pediatric | COMPLETED | NCT03344458 |
| TransCon hGH | Other | Phase PHASE3 | Growth Hormone Deficiency, Pediatric | COMPLETED | NCT03305016 |
| Placebo | Other | Phase PHASE3 | Hypoparathyroidism | COMPLETED | NCT04701203 |
| TransCon PTH | Other | Phase PHASE3 | Hypoparathyroidism | COMPLETED | NCT04701203 |
| Lonapegsomatropin | Other | Phase PHASE3 | Adult Growth Hormone Deficiency | COMPLETED | NCT05171855 |
| Somatropin | Other | Phase PHASE3 | Growth Hormone Deficiency | COMPLETED | NCT04615273 |
| Placebo | Other | Phase PHASE3 | Growth Hormone Deficiency | COMPLETED | NCT04615273 |
| Lonapegsomatropin | Other | Phase PHASE3 | Growth Hormone Deficiency | COMPLETED | NCT04615273 |
| Once daily subcutaneous injection of Genotropin | Other | Phase PHASE3 | Growth Hormone Deficiency, Pediatric | COMPLETED | NCT02781727 |
| Once weekly subcutaneous injection of TransCon hGH | Other | Phase PHASE3 | Growth Hormone Deficiency, Pediatric | COMPLETED | NCT02781727 |
| Placebo for TransCon CNP | Other | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04085523 |
| TransCon CNP | Other | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04085523 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Placebo for TransCon PTH | Other | Phase PHASE2 | Hypoparathyroidism | COMPLETED | NCT04009291 |
| TransCon PTH | Other | Phase PHASE2 | Hypoparathyroidism | COMPLETED | NCT04009291 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Somatropin | Other | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| Lonapegsomatropin | Other | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| Somatropin | Other | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| Lonapegsomatropin | Other | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| Somatropin | Other | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| Lonapegsomatropin | Other | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| Somatropin | Other | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| Lonapegsomatropin | Other | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| Somatropin | Other | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| Lonapegsomatropin | Other | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| Somatropin | Other | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| Lonapegsomatropin | Other | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Human Growth Hormone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01010425 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01010425 |
| ACP-001 (TransCon PEG hGH) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01010425 |
| Human Growth Hormone | Other | Phase PHASE2 | Growth Hormone Deficiency (GHD) | COMPLETED | NCT01947907 |
| ACP-001 | Other | Phase PHASE2 | Growth Hormone Deficiency (GHD) | COMPLETED | NCT01947907 |
| Omnitrope | Other | Phase PHASE2 | Adult Growth Hormone Deficiency | COMPLETED | NCT01247675 |
| ACP-001 (TransCon hGH) | Other | Phase PHASE2 | Adult Growth Hormone Deficiency | COMPLETED | NCT01247675 |
| TransCon Treprostinil | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT03803163 |
| daily hGH | Other | Phase PHASE3 | Growth Hormone Deficiency | UNKNOWN | NCT04326374 |
| TransCon hGH | Other | Phase PHASE3 | Growth Hormone Deficiency | UNKNOWN | NCT04326374 |
| TransCon hGH | Other | Phase PHASE3 | Growth Hormone Deficiency, Pediatric | COMPLETED | NCT03305016 |
| TransCon hGH | Other | Phase PHASE3 | Growth Hormone Deficiency, Pediatric | COMPLETED | NCT03305016 |
| Once daily subcutaneous injection of Genotropin | Other | Phase PHASE3 | Growth Hormone Deficiency, Pediatric | COMPLETED | NCT02781727 |
| Once weekly subcutaneous injection of TransCon hGH | Other | Phase PHASE3 | Growth Hormone Deficiency, Pediatric | COMPLETED | NCT02781727 |
| Once daily subcutaneous injection of Genotropin | Other | Phase PHASE3 | Growth Hormone Deficiency, Pediatric | COMPLETED | NCT02781727 |
| Once weekly subcutaneous injection of TransCon hGH | Other | Phase PHASE3 | Growth Hormone Deficiency, Pediatric | COMPLETED | NCT02781727 |
| Once daily subcutaneous injection of Genotropin | Other | Phase PHASE3 | Growth Hormone Deficiency, Pediatric | COMPLETED | NCT02781727 |
| Once weekly subcutaneous injection of TransCon hGH | Other | Phase PHASE3 | Growth Hormone Deficiency, Pediatric | COMPLETED | NCT02781727 |
| Placebo for TransCon CNP | Other | Phase PHASE2 | Achondroplasia | UNKNOWN | NCT05246033 |
| TransCon CNP | Other | Phase PHASE2 | Achondroplasia | UNKNOWN | NCT05246033 |
| TransCon hGH | Other | Phase PHASE3 | Growth Hormone Deficiency, Pediatric | COMPLETED | NCT03344458 |
| Somatropin | Other | Phase PHASE3 | Growth Hormone Deficiency | COMPLETED | NCT04615273 |
| Placebo | Other | Phase PHASE3 | Growth Hormone Deficiency | COMPLETED | NCT04615273 |
| Lonapegsomatropin | Other | Phase PHASE3 | Growth Hormone Deficiency | COMPLETED | NCT04615273 |
| Somatropin | Other | Phase PHASE3 | Growth Hormone Deficiency | COMPLETED | NCT04615273 |
| Placebo | Other | Phase PHASE3 | Growth Hormone Deficiency | COMPLETED | NCT04615273 |
| Lonapegsomatropin | Other | Phase PHASE3 | Growth Hormone Deficiency | COMPLETED | NCT04615273 |
| Somatropin | Other | Phase PHASE3 | Growth Hormone Deficiency | COMPLETED | NCT04615273 |
| Placebo | Other | Phase PHASE3 | Growth Hormone Deficiency | COMPLETED | NCT04615273 |
| Lonapegsomatropin | Other | Phase PHASE3 | Growth Hormone Deficiency | COMPLETED | NCT04615273 |
| Placebo for TransCon PTH | Other | Phase PHASE2 | Hypoparathyroidism | COMPLETED | NCT04009291 |
| TransCon PTH | Other | Phase PHASE2 | Hypoparathyroidism | COMPLETED | NCT04009291 |
| Placebo for TransCon CNP | Other | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04085523 |
| TransCon CNP | Other | Phase PHASE2 | Achondroplasia | COMPLETED | NCT04085523 |
| Palopegteriparatide (TransCon PTH) | Other | Preclinical | Hypoparathyroidism | APPROVED_FOR_MARKETING | NCT05654701 |
| Palopegteriparatide (TransCon PTH) | Other | Preclinical | Hypoparathyroidism | APPROVED_FOR_MARKETING | NCT05654701 |
| TransCon IL-2 β/γ | Other | Phase PHASE2 | Head and Neck Neoplasms | TERMINATED | NCT05980598 |
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Neoplasms | TERMINATED | NCT05980598 |
| TransCon TLR7/8 Agonist | Other | Phase PHASE2 | Head and Neck Neoplasms | TERMINATED | NCT05980598 |
| TransCon CNP | Other | Phase PHASE2 | Achondroplasia | ENROLLING_BY_INVITATION | NCT05929807 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Placebo for navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Lonapegsomatropin | Other | Phase PHASE3 | Adult Growth Hormone Deficiency | COMPLETED | NCT05171855 |
| Lonapegsomatropin | Other | Phase PHASE3 | Adult Growth Hormone Deficiency | COMPLETED | NCT05171855 |
| Somatropin | Other | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| Lonapegsomatropin | Other | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| Somatropin | Other | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| Lonapegsomatropin | Other | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| Placebo for TransCon CNP | Other | Phase PHASE2 | Achondroplasia | COMPLETED | NCT05598320 |
| TransCon CNP | Other | Phase PHASE2 | Achondroplasia | COMPLETED | NCT05598320 |
| Placebo for TransCon CNP | Other | Phase PHASE2 | Achondroplasia | COMPLETED | NCT05598320 |
| TransCon CNP | Other | Phase PHASE2 | Achondroplasia | COMPLETED | NCT05598320 |
| Placebo for TransCon CNP | Other | Phase PHASE2 | Achondroplasia | COMPLETED | NCT05598320 |
| TransCon CNP | Other | Phase PHASE2 | Achondroplasia | COMPLETED | NCT05598320 |
| No intervention | Other | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05775523 |
| No intervention | Other | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05775523 |
| No intervention | Other | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05775523 |
| Placebo | Other | Phase PHASE3 | Hypoparathyroidism | COMPLETED | NCT04701203 |
| TransCon PTH | Other | Phase PHASE3 | Hypoparathyroidism | COMPLETED | NCT04701203 |
| Placebo | Other | Phase PHASE3 | Hypoparathyroidism | COMPLETED | NCT04701203 |
| TransCon PTH | Other | Phase PHASE3 | Hypoparathyroidism | COMPLETED | NCT04701203 |
| Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections | Other | Phase PHASE2 | Achondroplasia | ACTIVE_NOT_RECRUITING | NCT06433557 |
| Trastuzumab emtansine (T-DM1) | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| Trastuzumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| Surgery | Procedure | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| TransCon TLR7/8 Agonist | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| Chemotherapy drug | Drug | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| TransCon IL-2 β/γ | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| Trastuzumab emtansine (T-DM1) | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| Trastuzumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| Surgery | Procedure | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| TransCon TLR7/8 Agonist | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| Chemotherapy drug | Drug | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| TransCon IL-2 β/γ | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| Palopegteriparatide | Other | Preclinical | Hypoparathyroidism | RECRUITING | NCT07345494 |
| Placebo for Navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06079398 |
| Navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06079398 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT04799054 |
| TransCon TLR7/8 Agonist | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT04799054 |
| Palopegteriparatide | Other | Preclinical | Hypoparathyroidism | RECRUITING | NCT07264634 |
| No intervention | Other | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05820672 |
| No intervention | Other | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05820672 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| No intervention | Other | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05820672 |
| Placebo for navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| No intervention | Other | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05820672 |
| Placebo for navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| No intervention | Other | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05820672 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Placebo for navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Placebo for navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| No intervention | Other | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05820672 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Placebo for navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| No intervention | Other | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05820672 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Placebo for navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| No intervention | Other | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05820672 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Placebo for navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Palopegteriparatide | Other | Preclinical | Hypoparathyroidism | RECRUITING | NCT07264634 |
| Palopegteriparatide | DRUG | Preclinical | Hypoparathyroidism | RECRUITING | NCT07345494 |
| Placebo for navepegritide | DRUG | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections | DRUG | Phase PHASE2 | Achondroplasia | ACTIVE_NOT_RECRUITING | NCT06433557 |
| Placebo for Navepegritide | DRUG | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06079398 |
| Navepegritide | DRUG | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06079398 |
| No intervention | OTHER | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05820672 |
| Palopegteriparatide (TransCon PTH) | DRUG | Preclinical | Hypoparathyroidism | APPROVED_FOR_MARKETING | NCT05654701 |
| Trastuzumab emtansine (T-DM1) | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| Trastuzumab | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| Surgery | PROCEDURE | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| Chemotherapy drug | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| TransCon IL-2 β/γ | DRUG | Phase PHASE2 | Head and Neck Neoplasms | TERMINATED | NCT05980598 |
| Pembrolizumab | DRUG | Phase PHASE2 | Head and Neck Neoplasms | TERMINATED | NCT05980598 |
| TransCon TLR7/8 Agonist | DRUG | Phase PHASE2 | Head and Neck Neoplasms | TERMINATED | NCT05980598 |
| Somatropin | DRUG | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| Lonapegsomatropin | BIOLOGICAL | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| daily hGH | DRUG | Phase PHASE3 | Growth Hormone Deficiency | UNKNOWN | NCT04326374 |
| Placebo for TransCon CNP | DRUG | Phase PHASE2 | Achondroplasia | COMPLETED | NCT05598320 |
| TransCon CNP | DRUG | Phase PHASE2 | Achondroplasia | ENROLLING_BY_INVITATION | NCT05929807 |
| TransCon Treprostinil | DRUG | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT03803163 |
| TransCon hGH | DRUG | Phase PHASE3 | Growth Hormone Deficiency | UNKNOWN | NCT04326374 |
| Once daily subcutaneous injection of Genotropin | DRUG | Phase PHASE3 | Growth Hormone Deficiency, Pediatric | COMPLETED | NCT02781727 |
| Once weekly subcutaneous injection of TransCon hGH | DRUG | Phase PHASE3 | Growth Hormone Deficiency, Pediatric | COMPLETED | NCT02781727 |
| ACP-001 | DRUG | Phase PHASE2 | Growth Hormone Deficiency (GHD) | COMPLETED | NCT01947907 |
| Omnitrope | DRUG | Phase PHASE2 | Adult Growth Hormone Deficiency | COMPLETED | NCT01247675 |
| ACP-001 (TransCon hGH) | DRUG | Phase PHASE2 | Adult Growth Hormone Deficiency | COMPLETED | NCT01247675 |
| Human Growth Hormone | DRUG | Phase PHASE2 | Growth Hormone Deficiency (GHD) | COMPLETED | NCT01947907 |
| Placebo | OTHER | Phase PHASE3 | Growth Hormone Deficiency | COMPLETED | NCT04615273 |
| ACP-001 (TransCon PEG hGH) | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01010425 |